| Summary: | 碩士 === 東海大學 === 化學系 === 99 === Alendronate is a bisphosphonate drug for treatment of osteoporosis. There are more than 80 countries (including Taiwan) which have approved the use of alendronate in the treatment and prevention of osteoporosis, corticosteroid-induced osteoporosis and Paget's disease. Alendronate is an amino compound that lacks UV or fluorescence chromophore, so derivatization is required prior to its absorption or fluorescent analysis. Currently, liquid chromatography with fluorescence detection is the main analytical method for alendronate, but complex sample pre-treatment, high sample consumption and poor resolution make it inferior to capillary electrophoresis.
In this study, alendronate is derivatized with NDA (2,3-naphthalene dicarboxyaldehyde) and CN- in alkaline conditions, followed by capillary electrophoresis / fluorescence analysis. Calibration range of alendronate in aqueous solution is 7-200 ppb and the detection limit (S / N = 3) is 2.1 ppb. Due to the complexity of urine sample matrix, sample purification is required before analysis. Fe3O4@Al2O3 magnetic nanoparticles (NPs) are used to extracte alendronate. Magnetic NPs have large specific surface area, higher biocompatibility and easy in magnetic collection.
The calibration range of alendronate in aqueous solution is 0.6-100 ppb after Fe3O4@Al2O3 NPs solid phase extraction. The detection limit is 0.18 ppb, the concentration factor is about 12 times, and the recovery is about 14 %. In alendronate-spiked urine samples, the calibration range is 5-100 ppb and the detection limit is 1.5 ppb.
Combining the characteristics of magnetic NPs, excellent resolution of capillary electrophoresis and highly sensitive fluorescence detection, we have developed a fast, convenient and sensitive analytical method for alendronate drug.
|
|---|
